Eisai Co., Ltd. company information, Employees & Contact Information

Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Co., Ltd.

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease Eisai Co., Ltd.

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia Biogen

Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China Eisai Co., Ltd.

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone ACN Newswire

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Early Alzheimer’s Disease in Mexico Biogen

Digital Asset Library Eisai US

The First 80 Years | Eisai Co., Ltd. Eisai Co., Ltd.

EISAI ESTABLISHES THEORIA TECHNOLOGIES CO., LTD., A NEW DIGITAL BUSINESS COMPANY TO BUILD A DEMENTIA ECOSYSTEM Eisai Co., Ltd.

“LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20 Eisai Co., Ltd.

EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN | News Release：2022 Eisai Co., Ltd.

Corporate Venture Capital Eisai Co., Ltd.

Eisai’s Efforts on Global Health ― An Interview of Scientists Working on Drug Discovery Eisai Co., Ltd.

Initiatives for Improving Access to Medicines Eisai Co., Ltd.

ANTIEPILEPTIC DRUG FYCOMPA® INJECTION FORMULATION LAUNCHED IN JAPAN Eisai Co., Ltd.

Production and Logistics (Demand Chain Systems) Eisai Co., Ltd.

Compliance and Risk Management Eisai Co., Ltd.

Alzheimer's Disease Treatment The Aricept R&D Story Eisai Co., Ltd.

Dementia Eisai Co., Ltd.

Discovering the Hidden Challenges: Understanding the Needs of the Alzheimer’s Disease Community Eisai US

Message from Top Management Eisai Co., Ltd.

Biomarker research for early diagnosis of Alzheimer's Eisai US

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status Biogen

Chapter 6 Breaking into the Top 20 Worldwide Eisai Co., Ltd.

EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS PR Newswire

Eisai co-establishes “Global Health Innovative Technology Fund,” Japan's first public–private partnership to eliminate infectious disease in developing countries | Research & Development for Improving Access to Medicines Eisai Co., Ltd.

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease Biogen

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China Biogen

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease Biogen

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA Biogen

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union Biogen

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership PR Newswire

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference Biogen

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia Biogen

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Biogen

Hackensack Meridian Health and Eisai Inc. Join Forces to Support the Expansion of Alzheimer's Disease Detection and Services for Patients PR Newswire

The U.S. FDA Accepts and Grants Priority Review for EISAI’s Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway Biogen

Eisai Inc. Deepens Its Commitment to Alzheimer's Disease with Key Executive Appointments PR Newswire

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel Biogen

Eisai Inc. Announces the Appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group PR Newswire

Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders PR Newswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China Biogen

Incidence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population Wiley

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea Biogen

Patrick Coyle Appointed Vice President and Chief Financial Officer of Eisai Inc. PR Newswire

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease Biogen

Eisai Commemorates Opening of Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts PR Newswire

Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen PR Newswire

Adriana Herrera Appointed Senior Vice President, Americas Commercial Oncology at Eisai Inc. PR Newswire

Eisai Appoints Dr. Andree Amelsberg as VP, U.S. Medical Affairs, Oncology Business Group citybiz

Rebecca Jolley appointed Senior Vice President Americas Commercial, Oncology Business Group at Eisai Inc. PR Newswire

Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day PR Newswire

Priya Chaturvedi, Ph.D., Appointed Vice President of Global Clinical Quality Assurance at Eisai Inc. PR Newswire

Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models Wiley Online Library

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China Stock Titan

Eisai Sells U.S. Rights to Zonegran® (zonisamide) Capsules to Concordia Pharmaceuticals Inc. PR Newswire

Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc. PR Newswire

"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" JCN Newswire

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series FinancialContent

Lecanemab Receives Priority Review Status in Japan FinancialContent

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium FinancialContent

Eisai Limited Bolsters Canadian Operations with Major Mississauga Expansion PR Newswire Canada

Eisai Limited celebrates opening of new Canadian headquarters PR Newswire Canada